126 related articles for article (PubMed ID: 38193270)
21. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism.
Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K
JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881
[TBL] [Abstract][Full Text] [Related]
22. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
23. Impact of oral anticoagulation choice on healthcare utilization for the primary treatment of venous thromboembolism.
Lutsey PL; MacLehose RF; Claxton JS; Walker RF; Adam TJ; Alonso A; Zakai NA
Vasc Med; 2020 Dec; 25(6):549-556. PubMed ID: 32716254
[TBL] [Abstract][Full Text] [Related]
24. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban.
Martins GL; Duarte RCF; Vieira ÉLM; Rocha NP; Figueiredo EL; Silveira FR; Caiaffa JRS; Lanna RP; Carvalho MDG; Palotás A; Ferreira CN; Reis HJ
Front Cardiovasc Med; 2020; 7():114. PubMed ID: 32793635
[No Abstract] [Full Text] [Related]
26. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.
Seaman CD; Smith KJ; Ragni MV
Thromb Res; 2013; 132(6):647-51. PubMed ID: 24139508
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
[TBL] [Abstract][Full Text] [Related]
28. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
[No Abstract] [Full Text] [Related]
29. Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study.
Coleman CI; Peacock WF; Bunz TJ; Beyer-Westendorf J
Thromb Res; 2018 Aug; 168():31-36. PubMed ID: 29883907
[TBL] [Abstract][Full Text] [Related]
30. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
[TBL] [Abstract][Full Text] [Related]
31. A retrospective study of real-world effectiveness and safety of rivaroxaban in patients with non-valvular atrial fibrillation and venous thromboembolism in Saudi Arabia.
Alosaimi HM; Alqahtani S; Balkhi B; Alqahtani M; Alzamil F; Alhossan A; Alqahtany FS; Alharbi AA; Alqahtani NA; Albackr H; Elgohary G; Algahtani FH
PeerJ; 2022; 10():e13974. PubMed ID: 36105646
[TBL] [Abstract][Full Text] [Related]
32. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
Patel AA; Ogden K; Mody SH; Bookhart B
J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
[TBL] [Abstract][Full Text] [Related]
33. Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registry.
Müller S; Tittl L; Speed V; Roberts L; Patel J; Patel R; Arya R; Kucher N; Spirk D; Sahin K; Beyer-Westendorf J
Res Pract Thromb Haemost; 2022 Oct; 6(7):e12829. PubMed ID: 36324830
[TBL] [Abstract][Full Text] [Related]
34. Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin.
Weaver P; Ng TH; Breeden T; Edwin SB; Haan B; ; Giuliano C
Ann Pharmacother; 2022 Dec; 56(12):1315-1324. PubMed ID: 35505606
[TBL] [Abstract][Full Text] [Related]
35. Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network.
Ruigómez A; Brobert G; Vora P; García Rodríguez LA
Pharmacoepidemiol Drug Saf; 2021 Feb; 30(2):229-236. PubMed ID: 33009708
[TBL] [Abstract][Full Text] [Related]
36. Viscoelastic properties of plasma fibrin clots are similar in patients on rivaroxaban and vitamin K antagonists.
Kopytek M; Zabczyk M; Natorska J; Siudut J; Malinowski KP; Ptaszek P; Glajcar A; Goralczyk T; Undas A
J Physiol Pharmacol; 2019 Feb; 70(1):. PubMed ID: 31019123
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and Safety of Rivaroxaban in Patients With Cancer-Associated Venous Thrombosis.
Kohn CG; Lyman GH; Beyer-Westendorf J; Spyropoulos AC; Bunz TJ; Baker WL; Eriksson D; Meinecke AK; Coleman CI
J Natl Compr Canc Netw; 2018 May; 16(5):491-497. PubMed ID: 29752323
[No Abstract] [Full Text] [Related]
38. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
39. Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism.
Coleman CI; Beyer-Westendorf J; Bunz TJ; Mahan CE; Spyropoulos AC
Clin Appl Thromb Hemost; 2018 May; 24(4):575-582. PubMed ID: 29514466
[TBL] [Abstract][Full Text] [Related]
40. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
